Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenues:
Total revenues	$ 81,106	$ 65,077	$ 150,261	$ 117,243
Cost and expenses:
Cost of revenues, excluding amortization of acquired intangible assets	4,065	3,502	6,672	4,033
Write-down of commercial supply and inventory to net realizable value and loss on non-cancellable purchase commitments	1,836	96	1,836	96
Research and development	38,932	37,344	75,437	71,046
Selling, general and administrative	68,363	57,792	127,864	113,396
Amortization of acquired intangible assets	3,476	421	6,952	841
Loss on fair value remeasurement of contingent consideration	1,962	6,933	2,474	8,547
Restructuring expenses	2,392		4,814
Total cost and expenses	121,026	106,088	226,049	197,959
Loss from operations	(39,920)	(41,011)	(75,788)	(80,716)
Other (expense) income:
Interest expense	(9,383)	(9,046)	(18,656)	(18,029)
Interest and investment income	732	496	1,413	891
(Loss) gain on derivatives	(809)	5,337	507	3,138
Loss on extinguishment of debt				(2,009)
Other expense, net	(9,460)	(3,213)	(16,736)	(16,009)
Net loss	$ (49,380)	$ (44,224)	$ (92,524)	$ (96,725)
Net loss per share—basic and diluted	$ (0.32)	$ (0.30)	$ (0.61)	$ (0.65)
Weighted average number of common shares used in net loss per share—basic and diluted:	152,163	148,778	151,591	148,285
Collaborative arrangements
Revenues:
Total revenues	$ 71,207	$ 58,640	$ 134,293	$ 110,504
Product
Revenues:
Total revenues	1,096	465	1,731	754
Active pharmaceutical ingredient
Revenues:
Total revenues	$ 8,803	$ 5,972	$ 14,237	$ 5,985